Royal Bank of Canada’s Kiora Pharmaceuticals KPRX Stock Holding History

Royal Bank of Canada’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5	Closed	-$4K	–	7790
2021 Q3	$4K	Hold	5	–	–	﹤0.01%	7202
2021 Q2	$6K	Hold	5	–	–	﹤0.01%	7024
2021 Q1	$8K	Hold	5	–	–	﹤0.01%	6892
2020 Q4	$8K	Hold	5	–	–	﹤0.01%	6479
2020 Q3	$7K	Hold	5	–	–	﹤0.01%	6042
2020 Q2	$8K	Hold	5	–	–	﹤0.01%	5912
2020 Q1	$9K	Hold	5	–	–	﹤0.01%	5861
2019 Q4	$17K	Buy	5 +3	+150%	+$5.82K	﹤0.01%	5927
2019 Q3	$3K	Hold	2	–	–	﹤0.01%	6198
2019 Q2	$3K	Hold	2	–	–	﹤0.01%	6479
2019 Q1	$4K	Hold	2	–	–	﹤0.01%	6342
2018 Q4	$6K	Hold	2	–	–	﹤0.01%	6103
2018 Q3	$4K	Hold	2	–	–	﹤0.01%	6343
2018 Q2	$7K	Hold	2	–	–	﹤0.01%	5930
2018 Q1	$5K	Buy	+2	New	+$8.64K	﹤0.01%	5925
2017 Q4	–	Hold	0	–	–	–	6717
2017 Q3	–	Hold	0	–	–	–	6836

Other funds holding KPRX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada's KPRX Position: Q4 2021 in Review

Royal Bank of Canada sold out of Kiora Pharmaceuticals (KPRX) in Q4 2021, closing a stake of 5 shares — an estimated $4K sold.

Royal Bank of Canada first reported a position in KPRX in Q1 2018 and held it in 15 quarters. The position peaked at $17K in Q4 2019. 11 funds tracked by Wall St. Rank hold KPRX as of Q4 2021.

Royal Bank of Canada reported no remaining Kiora Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Royal Bank of Canada sold 5 Kiora Pharmaceuticals shares in Q4 2021, an estimated $4K.
Royal Bank of Canada first reported a position in Kiora Pharmaceuticals in Q1 2018 and held it in 15 quarters.
Royal Bank of Canada's Kiora Pharmaceuticals position peaked at $17K in Q4 2019.
11 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2021.

Based on Royal Bank of Canada's 13F filing for Q4 2021, filed 14 Feb 2022.